


Amendments to the Claims

1. (Currently amended) A compound of formula (I)



or a tautomer thereof or a pharmaceutically acceptable salt of said compound or tautomer,

wherein

R<sup>1</sup> is a cyclic group selected from R<sup>A</sup>, R<sup>B</sup>, R<sup>C</sup> and R<sup>D</sup>, each of which is optionally substituted with one or more R<sup>7</sup> groups;

R<sup>2</sup> is hydrogen or C<sub>1</sub>-C<sub>2</sub> alkyl;

R<sup>3</sup> and R<sup>4</sup> are each independently C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl or C<sub>3</sub>-C<sub>10</sub> cycloalkyl, each of which is optionally substituted with one or more R<sup>8</sup> groups, or R<sup>E</sup>, which is optionally substituted with one or more R<sup>9</sup> groups, or hydrogen;

or -NR<sup>3</sup>R<sup>4</sup> forms R<sup>F</sup>, which is optionally substituted with one or more R<sup>10</sup> groups;

R<sup>5</sup> is -Y-NR<sup>15</sup>R<sup>16</sup>,

R<sup>6</sup>, which may be attached at N<sup>1</sup> or N<sup>2</sup>, is C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl or C<sub>2</sub>-C<sub>6</sub> alkynyl, each of which is optionally substituted by C<sub>1</sub>-C<sub>6</sub> alkoxy, (C<sub>3</sub>-C<sub>6</sub> cycloalkyl)methoxy, C<sub>1</sub>-C<sub>6</sub> haloalkoxy or a cyclic group selected from R<sup>I</sup>, R<sup>K</sup>, R<sup>L</sup> and R<sup>M</sup>, or R<sup>6</sup> is R<sup>N</sup>, C<sub>3</sub>-C<sub>7</sub> cycloalkyl or C<sub>3</sub>-C<sub>7</sub> halocycloalkyl, each of which is optionally substituted by C<sub>1</sub>-C<sub>6</sub> alkoxy or C<sub>1</sub>-C<sub>6</sub> haloalkoxy, or R<sup>6</sup> is hydrogen;

R<sup>7</sup> is halo, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, C<sub>3</sub>-C<sub>10</sub> halocycloalkyl, phenyl, OR<sup>12</sup>, OC(O)R<sup>12</sup>, NO<sub>2</sub>, NR<sup>12</sup>R<sup>13</sup>, NR<sup>12</sup>C(O)R<sup>13</sup>, NR<sup>12</sup>CO<sub>2</sub>R<sup>14</sup>, C(O)R<sup>12</sup>, CO<sub>2</sub>R<sup>12</sup>, CONR<sup>12</sup>R<sup>13</sup> or CN;

R<sup>8</sup> is halo, phenyl, C<sub>1</sub>-C<sub>6</sub> alkoxyphenyl, OR<sup>12</sup>, OC(O)R<sup>12</sup>, NO<sub>2</sub>, NR<sup>12</sup>R<sup>13</sup>, NR<sup>12</sup>C(O)R<sup>13</sup>, NR<sup>12</sup>CO<sub>2</sub>R<sup>14</sup>, C(O)R<sup>12</sup>, CO<sub>2</sub>R<sup>12</sup>, CONR<sup>12</sup>R<sup>13</sup>, CN, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, R<sup>9</sup> or R<sup>4</sup>, the last two of which are optionally substituted with one or more R<sup>9</sup> groups;

R<sup>9</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl or CO<sub>2</sub>R<sup>12</sup>;

R<sup>10</sup> is halo, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, C<sub>3</sub>-C<sub>10</sub> halocycloalkyl, phenyl, OR<sup>12</sup>, OC(O)R<sup>12</sup>, NO<sub>2</sub>, NR<sup>12</sup>R<sup>13</sup>, NR<sup>12</sup>C(O)R<sup>13</sup>, NR<sup>12</sup>CO<sub>2</sub>R<sup>14</sup>, C(O)R<sup>12</sup>, CO<sub>2</sub>R<sup>13</sup>, CONR<sup>12</sup>R<sup>13</sup>, CN, oxo, C<sub>1</sub>-C<sub>6</sub> alkyl or C<sub>1</sub>-C<sub>6</sub> haloalkyl, the last two of which are optionally substituted by R<sup>11</sup>;

R<sup>11</sup> is phenyl, NR<sup>12</sup>R<sup>13</sup> or NR<sup>12</sup>CO<sub>2</sub>R<sup>14</sup>;

R<sup>12</sup> and R<sup>13</sup> are each independently hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl or C<sub>1</sub>-C<sub>6</sub> haloalkyl;

R<sup>14</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl or C<sub>1</sub>-C<sub>6</sub> haloalkyl;

R<sup>15</sup> is selected from R<sup>17</sup>, R<sup>17</sup>C(O) and R<sup>18</sup>SO<sub>2</sub>, and

R<sup>16</sup> is selected from hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with one or more R<sup>19</sup> groups, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>3</sub>-C<sub>10</sub> cycloalkyl optionally substituted with one or more R<sup>20</sup> groups,

or -NR<sup>16</sup>R<sup>16</sup> constitutes a 3- to 8-membered saturated ring ~~which may optionally include~~ containing one or more further heteroatoms in addition to said nitrogen selected from nitrogen, oxygen and sulphur, and which may optionally be substituted with one or more groups selected from R<sup>21</sup>, R<sup>22</sup> and (C<sub>1</sub>-C<sub>6</sub> alkoxy)C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sup>17</sup> is hydrogen or R<sup>18</sup>;

R<sup>18</sup> is selected from C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with one or more R<sup>19</sup> groups, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>3</sub>-C<sub>10</sub> cycloalkyl optionally substituted with one or more R<sup>20</sup> groups;

R<sup>19</sup> is selected from R<sup>21</sup>, -NR<sup>23</sup>R<sup>24</sup>, -CO<sub>2</sub>R<sup>25</sup>, -CONR<sup>26</sup>R<sup>27</sup>, R<sup>28</sup> and phenyl optionally substituted by R<sup>29</sup>;

R<sup>20</sup> is selected from R<sup>21</sup>, R<sup>22</sup> and oxo;

R<sup>21</sup> is oxo, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> (haloalkyl)oxy or C<sub>3</sub>-C<sub>7</sub> cycloalkyloxy;

R<sup>22</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl or C<sub>1</sub>-C<sub>6</sub> haloalkyl;

R<sup>23</sup> and R<sup>24</sup> are each independently selected from hydrogen and C<sub>1</sub>-C<sub>6</sub> alkyl;

or -NR<sup>23</sup>R<sup>24</sup> constitutes an azetidine, pyrrolidine, piperidine or morpholine ring;

R<sup>25</sup> is hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sup>26</sup> and R<sup>27</sup> are each independently selected from hydrogen and C<sub>1</sub>-C<sub>6</sub> alkyl;

or -NR<sup>26</sup>R<sup>27</sup> constitutes an azetidine, pyrrolidine, piperidine or morpholine ring;

R<sup>28</sup> is a saturated, unsaturated or aromatic heterocycle with up to 10 ring atoms, at least one of which is selected from nitrogen, oxygen and sulphur;

R<sup>29</sup> is selected from halo, R<sup>21</sup> and R<sup>22</sup>,

R<sup>A</sup> and R<sup>J</sup> are each independently a C<sub>3</sub>-C<sub>10</sub> cycloalkyl or C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, each of which may be either monocyclic or, when there are an appropriate number of ring atoms, polycyclic and which may be fused to either

(a) a monocyclic aromatic ring selected from a benzene ring and a 5- or 6-membered heteroaromatic ring containing up to three heteroatoms selected from nitrogen, oxygen and sulphur, or

(b) a 5-, 6- or 7-membered heteroalicyclic ring containing up to three heteroatoms selected from nitrogen, oxygen and sulphur;

R<sup>B</sup> and R<sup>K</sup> are each independently a phenyl or naphthyl group, each of which may be fused to

(a) a C<sub>5</sub>-C<sub>7</sub> cycloalkyl or C<sub>5</sub>-C<sub>7</sub> cycloalkenyl ring,

(b) a 5-, 6- or 7-membered heteroalicyclic ring containing up to three heteroatoms selected from nitrogen, oxygen and sulphur, or

(c) a 5- or 6-membered heteroaromatic ring containing up to three heteroatoms selected from nitrogen, oxygen and sulphur;

$R^C$ ,  $R^L$  and  $R^N$  are each independently a monocyclic or, when there are an appropriate number of ring atoms, polycyclic saturated or partly unsaturated ring system containing between 3 and 10 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur, which ring may be fused to a  $C_5$ - $C_7$  cycloalkyl or  $C_5$ - $C_7$  cycloalkenyl group or a monocyclic aromatic ring selected from a benzene ring and a 5- or 6-membered heteroaromatic ring containing up to three heteroatoms selected from nitrogen, oxygen and sulphur;

$R^D$  and  $R^M$  are each independently a 5- or 6-membered heteroaromatic ring containing up to three heteroatoms independently selected from nitrogen, oxygen and sulphur, which ring may further be fused to

- (a) a second 5- or 6-membered heteroaromatic ring containing up to three heteroatoms selected from nitrogen, oxygen and sulphur;
- (b)  $C_5$ - $C_7$  cycloalkyl or  $C_5$ - $C_7$  cycloalkenyl ring;
- (c) a 5-, 6- or 7-membered heteroalicyclic ring containing up to three heteroatoms selected from nitrogen, oxygen and sulphur; or
- (d) a benzene ring;

$R^E$ ,  $R^F$  and  $R^G$  are each independently a monocyclic or, when there are an appropriate number of ring atoms, polycyclic saturated ring system containing between 3 and 10 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur;

$R^H$  is a 5- or 6-membered heteroaromatic ring containing up to three heteroatoms independently selected from nitrogen, oxygen and sulphur; and

Y is a covalent bond,  $C_1$ - $C_6$  alkylenyl or  $C_3$ - $C_7$  cycloalkylenyl ;

~~a tautomer thereof or a pharmaceutically acceptable salt, solvate or polymorph of said compound or tautomer.~~

2. (Original) A compound according to claim 1 wherein  $R^1$  is  $R^B$ , which is optionally substituted with one or more  $R^7$  groups.

3. (Original) A compound according to claim 1 wherein  $R^1$  is  $R^D$ , which is optionally substituted with one or more  $R^7$  groups.
4. (Original) A compound according to claim 1 wherein  $R^7$  is halo,  $C_1-C_6$  alkyl,  $C_1-C_6$  haloalkyl,  $OR^{12}$  or  $CONR^{12}R^{13}$ .
5. (Original) A compound according to claim 1 wherein  $R^2$  is hydrogen.
6. (Original) A compound according to claim 1 wherein  $R^3$  is hydrogen,  $C_1-C_6$  alkyl, which is optionally substituted with one or more  $R^8$  groups, or  $R^E$ , which is optionally substituted with one or more  $R^9$  groups; and wherein  $R^E$  is a monocyclic or, when there are an appropriate number of ring atoms, polycyclic saturated ring system containing between 3 and 7 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur.
7. (Original) A compound according to claim 1 wherein  $R^4$  is hydrogen,  $C_1-C_6$  alkyl,  $C_1-C_6$  haloalkyl,  $C_2-C_6$  alkenyl or  $C_2-C_6$  alkynyl.
8. (Original) A compound according to claim 1 wherein  $-NR^3R^4$  forms  $R^F$ , which is optionally substituted with one or more  $R^{10}$  groups and wherein  $R^F$  is a monocyclic or, when there are an appropriate number of ring atoms, polycyclic saturated ring system containing between 3 and 10 ring atoms containing at least one nitrogen atom and optionally one other atom selected from oxygen and sulphur.
9. (Original) A compound according to claim 1 wherein Y is  $C_1-C_6$  alkylenyl.
10. (Original) A compound according to claim 1 wherein  $R^{15}$  is  $R^{17}C(O)$  or  $R^{16}SO_2$  and  $R^{16}$  is hydrogen or  $C_1-C_6$  alkyl.
11. (Original) A compound according to claim 1 wherein  $R^{15}$  is  $R^{17}$  and  $R^{16}$  is hydrogen or  $C_1-C_6$  alkyl.
12. (Currently amended) A compound according to claim 1 wherein  $-NR^{15}R^{16}$  constitutes a 3- to 8-membered saturated ring ~~which may optionally include~~ containing one or more ~~further~~ heteroatoms in addition to said nitrogen selected from

nitrogen, oxygen and sulphur, and which may optionally be substituted with one or more groups selected from  $R^{21}$ ,  $R^{22}$  and  $(C_1-C_6 \text{ alkoxy})C_1-C_6 \text{ alkyl}$ .

13. (Original) A compound according to claim 1 wherein  $R^6$  is positioned on  $N^1$ .

14. (Original) A compound according to claim 1 wherein

$R^6$  is  $C_1-C_6$  alkyl or  $C_1-C_6$  haloalkyl, each of which is optionally substituted by  $C_1-C_6$  alkoxy,  $C_1-C_6$  haloalkoxy or a cyclic group selected from  $R^J$ ,  $R^L$  and  $R^M$ , or  $R^6$  is  $R^N$  or hydrogen;

$R^J$  is a  $C_3-C_7$  monocyclic cycloalkyl group;

$R^L$  and  $R^N$  are each independently a monocyclic, saturated or partly unsaturated ring system containing between 4 and 7 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur; and

$R^M$  is a 5- or 6-membered heteroaromatic ring containing up to three heteroatoms independently selected from nitrogen, oxygen and sulphur.

15. (Original) A compound according to claim 1 wherein

$R^3$  is hydrogen,  $C_1-C_4$  alkyl, which is optionally substituted with one or more  $R^8$  groups, or  $R^E$ , which is optionally substituted with one or more  $R^9$  groups;

$R^4$  is hydrogen,  $C_1-C_6$  alkyl or  $C_1-C_6$  haloalkyl;

or  $-NR^3R^4$  forms  $R^F$ , which is optionally substituted with one or more  $R^{10}$  groups;

$R^6$  is  $C_1-C_4$  alkyl or  $C_1-C_4$  haloalkyl, each of which is optionally substituted by  $C_1-C_4$  alkoxy,  $C_1-C_4$  haloalkoxy or a cyclic group selected from  $R^J$ ,  $R^L$  and  $R^M$ , or  $R^6$  is  $R^N$  or hydrogen;

$R^A$  is a monocyclic  $C_3-C_6$  cycloalkyl group;

$R^B$  is phenyl;

R<sup>C</sup> is a monocyclic saturated or partly unsaturated ring system containing between 3 and 8 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur;

R<sup>D</sup> is a 5- or 6-membered heteroaromatic ring containing up to three heteroatoms independently selected from nitrogen, oxygen and sulphur;

R<sup>E</sup> is a monocyclic saturated ring system containing between 3 and 7 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur;

R<sup>F</sup> is a monocyclic or, when there are an appropriate number of ring atoms, polycyclic saturated ring system containing between 3 and 10 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur;

R<sup>J</sup> is cyclopropyl or cyclobutyl;

R<sup>L</sup> and R<sup>N</sup> are each independently a monocyclic saturated ring system containing either 5 or 6 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur;

R<sup>M</sup> is a 5- or 6-membered heteroaromatic ring containing a heteroatom selected from nitrogen, oxygen and sulphur; and

Y is C<sub>1</sub>-C<sub>8</sub> alkylenyl.

16. (Currently amended) A compound according to claim 15 wherein R<sup>1</sup> is a cyclic group selected from R<sup>A</sup>, R<sup>B</sup>, R<sup>C</sup> and R<sup>D</sup>, each of which is optionally substituted with one or more R<sup>7</sup> groups;

R<sup>7</sup> is halo, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, OR<sup>12</sup> or CONR<sup>12</sup>R<sup>13</sup>;

R<sup>8</sup> is halo, phenyl, C<sub>1</sub>-C<sub>6</sub> alkoxyphenyl, OR<sup>12</sup>, NR<sup>12</sup>R<sup>13</sup>, NR<sup>12</sup>CO<sub>2</sub>R<sup>14</sup>, CO<sub>2</sub>R<sup>12</sup>, CONR<sup>12</sup>R<sup>13</sup>, R<sup>G</sup> or R<sup>H</sup>, the last two of which are optionally substituted with one or more R<sup>9</sup> groups;

R<sup>A</sup> is a monocyclic C<sub>5</sub>-C<sub>7</sub> cycloalkyl group;

R<sup>B</sup> is phenyl;

R<sup>C</sup> is a monocyclic saturated ring system containing between 5 and 7 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur;

R<sup>D</sup> is a 5-membered heteroaromatic ring containing a heteroatom selected from nitrogen, oxygen and sulphur and optionally up to two further nitrogen atoms in the ring, or a 6-membered heteroaromatic ring containing including 1, 2 or 3 nitrogen atoms;

R<sup>E</sup> is a monocyclic saturated ring system containing between 3 and 7 ring atoms containing one nitrogen atom;

R<sup>F</sup> is a monocyclic or, when there are an appropriate number of ring atoms, polycyclic saturated ring system containing between 3 and 10 ring atoms containing at least one nitrogen atom and optionally one other atom selected from oxygen and sulphur;

R<sup>G</sup> is a monocyclic saturated ring system containing between 3 and 7 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur;

R<sup>H</sup> is a 5- or 6-membered heteroaromatic ring containing up to two nitrogen atoms; and

Y is -CH<sub>2</sub>-.

17. (Currently amended) A pharmaceutical composition comprising a compound of ~~formula (I) as claimed in claim 1, or a~~ pharmaceutically acceptable salt ~~salts, solvates or polymorphs~~ thereof, and a pharmaceutically acceptable diluent or carrier.

18. (Canceled)

20. (Currently amended) A method of treating a disorder or condition in a mammal, which method comprises administering to said mammal a compound of Claim 1 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of Claim 1 or a pharmaceutically acceptable salt thereof and a



pharmaceutically acceptable diluent or carrier, according to claim 18, wherein the disorder or condition is hypertension.